IGF-1 and IGF-1 LR3: Complete Guide to the Growth Factor and Its Analogue

Almost no IGF-1 travels alone. Six distinct IGF-binding proteins (IGFBPs) bind it with an affinity equal to or greater than the IGF-1 receptor's. In serum, about 75-80% of IGFs sit in a roughly 150-kDa ternary complex with IGFBP-3 (less often IGFBP-5) and a glycoprotein called the acid-labile subunit; most of the rest is bound to the other IGFBPs.^[2]

Binding changes how IGF-1 behaves. Unbound IGFs have a circulating half-life of under 10 minutes, binding to an IGFBP extends it, and the large ternary complex keeps IGF-1 in the bloodstream. Binding also blocks IGF-1 from acting on the insulin receptor and lets tissues control where and when the growth factor is released to its receptor.^[2]

This buffering is the key to understanding IGF-1 LR3. Its design goal was not a stronger fit to the receptor but an escape from the binding proteins, and that single change explains both its higher potency in some experiments and its faster clearance in others.^[5][6]

IGF-1 LR3, also written Long R3 IGF-I or LR3IGF-I, was produced in the early 1990s by an Australian research group as a recombinant fusion protein. It consists of the first 11 amino acids of methionyl porcine growth hormone, a Val-Asn linker, and the full IGF-1 sequence with the glutamate at position 3 replaced by arginine. That adds 13 residues to IGF-1's 70, which is why the analogue is usually described as 83 amino acids long.^[5][1]

In rat L6 myoblasts, which secrete binding proteins, the long analogues were more potent than IGF-1 at stimulating protein and DNA synthesis and at inhibiting protein breakdown, with Long [Arg3]-IGF-I among the most potent. In chicken embryo fibroblasts, which do not secrete detectable binding proteins, it was less potent than IGF-1. The gain, in other words, depends on the presence of IGFBPs.^[5]

Later measurements quantified the trade-off. IGF-1 has roughly a thousand-fold higher affinity than LR3IGF-I for IGFBP-3, IGFBP-4 and total rat plasma binding proteins, which gave LR3IGF-I five to ten times the potency in cultured myoblasts. At the IGF-1 receptor itself, LR3IGF-I binds about three-fold less well than IGF-1.^[6][8]

'Long' refers to the N-terminal extension, not to how long the molecule lasts. The '20 to 30 hours' figure repeated on many sites has no primary source that we could find, and the animal measurements point the other way. In rats given radiolabelled tracers intravenously, LR3IGF-I was cleared from plasma far faster than IGF-1: a metabolic clearance rate of about 9.2-9.8 mL/min per kg, against 0.90 for IGF-1 in non-pregnant animals, with most LR3IGF-I circulating as free peptide.^[7]

The explanation is the binding proteins. Because LR3IGF-I barely associates with them, it misses the protective 150-kDa complex and is removed from the blood much more rapidly than IGF-1. The point was confirmed in pregnant rats, whose binding-protein levels fall sharply: only IGF-1's clearance changed, speeding up almost to the rate seen with LR3IGF-I.^[6][7]

An anti-doping study reached the same conclusion by a different route: after a single intramuscular dose in rats, intact LongR3-IGF-I disappeared from blood after about 4 hours, while N-terminally truncated breakdown products remained detectable for up to 16 hours. Its effects can still outlast its presence; in pigs and marmosets, the low-binding variants lowered blood glucose for longer than IGF-1 despite their faster clearance.^[12][10]

The anabolic reputation comes from rats. In young male rats made catabolic with dexamethasone, IGF-1 delivered by osmotic pump partly reversed weight and nitrogen loss, and LR3IGF-I was about 2.5-fold more potent than IGF-1. Muscle protein synthesis and breakdown both shifted in an anabolic direction, but part of the response was growth of the gut, which increased in weight by up to 45%.^[8]

In growing female rats treated for 14 days, IGF-1 increased weight gain, nitrogen retention and food-conversion efficiency by 18-26% at the highest dose, and a much smaller amount of LR3IGF-I produced similar effects. Organ and carcass measurements showed that body proportions were largely maintained, and muscle protein synthesis and breakdown rose only slightly.^[9]

The result did not carry across species. In finisher pigs, a four-day LR3IGF-I infusion decreased daily weight gain and food intake and lowered plasma IGFBP-3, IGF-1 and insulin. Mean GH fell by 23% and the area under the GH peaks by 60%, and adding porcine GH did not restore growth. The authors concluded that suppression of the animal's own GH axis may explain why LR3IGF-I inhibited growth in pigs.^[11]

No. A 2026 endocrine review that sorted GH-axis peptides into evidence tiers placed IGF-1 LR3 in its lowest tier, with no peer-reviewed human studies and support only from preclinical extrapolation and user narratives. An anti-doping laboratory describes the IGF-1 analogues as never approved for use in humans. Everything written about LR3's effects in people is therefore inference.^[18][12]

Native IGF-1 does have a human record. Recombinant IGF-1, mecasermin, has been authorised in the EU since 2007 as Increlex for the long-term treatment of children and adolescents with severe primary IGF-1 deficiency, a rare growth disorder; the EMA's summary lists hypoglycaemia among its common side effects and rules it out in patients with active or suspected neoplasia.^[17]

Outside that indication the human results are sobering. In a randomised, placebo-controlled trial in healthy women over 60, a year of twice-daily IGF-1 raised blood IGF-1 into the young-adult range but changed nothing measured: not bone density, lean mass, fat mass, strength, lipids, mood or memory. The study was stopped after 16 participants because no outcome was moving.^[15]

Low blood sugar is the most direct risk of this insulin-related growth factor. In pigs and marmoset monkeys, IGF-1 variants that bind poorly to IGFBPs, LR3IGF-I among them, were two to three times more potent than IGF-1 at lowering plasma glucose, and the cumulative glucose suppression over four hours was about four to eight times greater. For native IGF-1, the EMA lists hypoglycaemia among mecasermin's common side effects.^[10][17]

Growth signalling is the second, longer-term concern. A meta-analysis of 21 studies with 3,609 cancer cases found that higher circulating IGF-1 was associated with a modestly increased risk of prostate cancer and premenopausal breast cancer. That is an association in observational data about the body's own IGF-1, not proof that an analogue causes cancer; separately, the authorised IGF-1 medicine must not be used in patients with active or suspected neoplasia.^[16][17]

The third risk is the product itself. Anti-doping chemists found a black-market injection vial containing Long-R3-IGF-I with a His-tag still attached, a purification handle used in laboratory production, and noted that its effects in humans have never been described. Another laboratory found abundant oxidised, lower-quality forms of the analogue in black-market products.^[13][12]

IGF-1 LR3 has never been approved for use in humans. In the EU, the authorised IGF-1 medicine is mecasermin, a copy of native IGF-1, for a narrow paediatric indication. In sport, the WADA 2026 Prohibited List names insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues under S2.3, growth factors and growth factor modulators, a class prohibited at all times.^[12][17][19]

The analogue does have an established laboratory role. In serum-free cultures of Chinese hamster ovary cells producing recombinant proteins, LongR3 could replace insulin as the growth factor and sustained cell viability under production conditions better than insulin did. That laboratory use, not human physiology, is where the analogue has a documented purpose.^[14]

Peptyds supplies IGF-1 LR3 as a lyophilised compound with a batch certificate of analysis, for in-vitro laboratory research only. We do not present it as a muscle-building, recovery or anti-ageing product, and we do not describe it as long-acting, because the published pharmacokinetics say otherwise.^[7]